239 related articles for article (PubMed ID: 30353265)
1. RNA-seq for identification of therapeutically targetable determinants of immune activation in human glioblastoma.
Bagley SJ; Hwang WT; Brem S; Linette GP; O'Rourke DM; Desai AS
J Neurooncol; 2019 Jan; 141(1):95-102. PubMed ID: 30353265
[TBL] [Abstract][Full Text] [Related]
2. Computational Characterization of Suppressive Immune Microenvironments in Glioblastoma.
Luoto S; Hermelo I; Vuorinen EM; Hannus P; Kesseli J; Nykter M; Granberg KJ
Cancer Res; 2018 Oct; 78(19):5574-5585. PubMed ID: 29921698
[TBL] [Abstract][Full Text] [Related]
3. Higher cytolytic score correlates with an immunosuppressive tumor microenvironment and reduced survival in glioblastoma.
Haddad AF; Chen JS; Oh T; Pereira MP; Joshi RS; Aghi MK
Sci Rep; 2020 Oct; 10(1):17580. PubMed ID: 33067480
[TBL] [Abstract][Full Text] [Related]
4. Tumor Microenvironment Characterization in Glioblastoma Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures.
Zhang J; Xiao X; Zhang X; Hua W
J Mol Neurosci; 2020 May; 70(5):738-750. PubMed ID: 32006162
[TBL] [Abstract][Full Text] [Related]
5. Analysis of immunobiologic markers in primary and recurrent glioblastoma.
Rahman M; Kresak J; Yang C; Huang J; Hiser W; Kubilis P; Mitchell D
J Neurooncol; 2018 Apr; 137(2):249-257. PubMed ID: 29302887
[TBL] [Abstract][Full Text] [Related]
6. Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment.
Jeanmougin M; Håvik AB; Cekaite L; Brandal P; Sveen A; Meling TR; Ågesen TH; Scheie D; Heim S; Lothe RA; Lind GE
Mol Oncol; 2020 May; 14(5):1016-1027. PubMed ID: 32171051
[TBL] [Abstract][Full Text] [Related]
7. Establishment and validation of an immune-based prognostic score model in glioblastoma.
Qin Z; Zhang X; Chen Z; Liu N
Int Immunopharmacol; 2020 Aug; 85():106636. PubMed ID: 32534425
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.
Han J; Puri RK
J Neurooncol; 2018 Feb; 136(3):463-474. PubMed ID: 29168083
[TBL] [Abstract][Full Text] [Related]
9. A novel Foxp3-related immune prognostic signature for glioblastoma multiforme based on immunogenomic profiling.
Guo XY; Zhang GH; Wang ZN; Duan H; Xie T; Liang L; Cui R; Hu HR; Wu Y; Dong JJ; He ZQ; Mou YG
Aging (Albany NY); 2021 Jan; 13(3):3501-3517. PubMed ID: 33429364
[TBL] [Abstract][Full Text] [Related]
10. Identification of Immune Cell Infiltration and Immune-Related Genes in the Tumor Microenvironment of Glioblastomas.
Huang S; Song Z; Zhang T; He X; Huang K; Zhang Q; Shen J; Pan J
Front Immunol; 2020; 11():585034. PubMed ID: 33193404
[TBL] [Abstract][Full Text] [Related]
11. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.
Brown CE; Aguilar B; Starr R; Yang X; Chang WC; Weng L; Chang B; Sarkissian A; Brito A; Sanchez JF; Ostberg JR; D'Apuzzo M; Badie B; Barish ME; Forman SJ
Mol Ther; 2018 Jan; 26(1):31-44. PubMed ID: 29103912
[TBL] [Abstract][Full Text] [Related]
12. The role of checkpoints in the treatment of GBM.
Kim JE; Lim M
J Neurooncol; 2015 Jul; 123(3):413-23. PubMed ID: 25749875
[TBL] [Abstract][Full Text] [Related]
13. Tumor antigen-specific T cells for immune monitoring of dendritic cell-treated glioblastoma patients.
Müller I; Altherr D; Eyrich M; Flesch B; Friedmann KS; Ketter R; Oertel J; Schwarz EC; Technau A; Urbschat S; Eichler H
Cytotherapy; 2016 Sep; 18(9):1146-61. PubMed ID: 27424145
[TBL] [Abstract][Full Text] [Related]
14. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
15. Construction of Interferon-Gamma-Related Gene Signature to Characterize the Immune-Inflamed Phenotype of Glioblastoma and Predict Prognosis, Efficacy of Immunotherapy and Radiotherapy.
Ji H; Ba Y; Ma S; Hou K; Mi S; Gao X; Jin J; Gong Q; Liu T; Wang F; Liu Z; Li S; Du J; Hu S
Front Immunol; 2021; 12():729359. PubMed ID: 34566988
[TBL] [Abstract][Full Text] [Related]
16. Immune Cytolytic Activity Is Associated With Genetic and Clinical Properties of Glioma.
Wang ZL; Wang Z; Li GZ; Wang QW; Bao ZS; Zhang CB; Jiang T
Front Immunol; 2019; 10():1756. PubMed ID: 31428092
[No Abstract] [Full Text] [Related]
17. Emerging immunotherapies for glioblastoma.
Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
[TBL] [Abstract][Full Text] [Related]
18. BACH1 as a potential target for immunotherapy in glioblastomas.
Yuan F; Cong Z; Cai X; Zhu J; Yuan L; Wang Y; Tang C; Ma C
Int Immunopharmacol; 2022 Feb; 103():108451. PubMed ID: 34923423
[TBL] [Abstract][Full Text] [Related]
19. Identification of a unique tumor cell subset employing myeloid transcriptional circuits to create an immunomodulatory microenvironment in glioblastoma.
Yang K; Shi Y; Luo M; Mao M; Zhang X; Chen C; Liu Y; He Z; Liu Q; Wang W; Luo C; Yin W; Wang C; Niu Q; Zeng H; Bian XW; Ping YF
Oncoimmunology; 2022; 11(1):2030020. PubMed ID: 35096487
[TBL] [Abstract][Full Text] [Related]
20. Cytolytic Activity Score to Assess Anticancer Immunity in Colorectal Cancer.
Narayanan S; Kawaguchi T; Yan L; Peng X; Qi Q; Takabe K
Ann Surg Oncol; 2018 Aug; 25(8):2323-2331. PubMed ID: 29770915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
